Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice
Y Tamura, M Sugimoto, T Murayama… - … , and vascular biology, 2008 - Am Heart Assoc
Arteriosclerosis, thrombosis, and vascular biology, 2008•Am Heart Assoc
Objective—Recently, adipose tissue inflammation induced by macrophage infiltration
through MCP-1/CC chemokine receptor-2 (CCR2) pathway is considered to play a role in
the development of visceral obesity and insulin resistance. In the present study, to further
examine the role of CCR2 in the development of obesity and type 2 diabetes, we studied the
effect of pharmacological inhibition of CCR2 from the early stage of obesity in db/db mice.
Methods and Results—Db/+ m (lean control) and db/db mice were fed with a standard diet …
through MCP-1/CC chemokine receptor-2 (CCR2) pathway is considered to play a role in
the development of visceral obesity and insulin resistance. In the present study, to further
examine the role of CCR2 in the development of obesity and type 2 diabetes, we studied the
effect of pharmacological inhibition of CCR2 from the early stage of obesity in db/db mice.
Methods and Results—Db/+ m (lean control) and db/db mice were fed with a standard diet …
Objective— Recently, adipose tissue inflammation induced by macrophage infiltration through MCP-1/C-C chemokine receptor-2 (CCR2) pathway is considered to play a role in the development of visceral obesity and insulin resistance. In the present study, to further examine the role of CCR2 in the development of obesity and type 2 diabetes, we studied the effect of pharmacological inhibition of CCR2 from the early stage of obesity in db/db mice.
Methods and Results— Db/+m (lean control) and db/db mice were fed with a standard diet with or without 0.005% propagermanium, as a CCR2 inhibitor for 12 weeks from 6 weeks of age. Propagermanium treatment decreased body weight gain, visceral fat accumulation, and the size of adipocytes only in db/db mice. Further, propagermanium suppressed macrophage accumulation and inflammation in adipose tissue. Propagermanium treatment also ameliorated glucose tolerance and insulin sensitivity, and decreased hepatic triglyceride contents in db/db mice.
Conclusions— Propagermanium improved obesity and related metabolic disorders, such as insulin resistance and hepatic steatosis by suppressing inflammation in adipose tissue. Our data indicate that inhibition of CCR2 could improve obesity and type 2 diabetes by interfering adipose tissue inflammation, and that propagermanium may be a beneficial drug for the treatment of the metabolic syndrome.
Am Heart Assoc